(Q24250281)

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine and levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

The comparative value of amantadine and levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine versus L-2 dopa and amatadine plus L-dopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine therapy in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Combined treatment of parkinsonism with L-dopa and amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Amantadine for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Treatment of Parkinson's disease with amantadine and levodopa. A one-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Combined L-Dopa and Amantadine in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Treatment of Parkinson’s Disease with Amantadine and L-Dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used in combination in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD003468

1 reference

7 January 2021

Controlled trial of amantadine hydrochloride in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

Amantadine dosage in treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

Combined treatment of parkinsonism with L-dopa and amantadine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

Treatment of Parkinsonism with L-dopa and amantadine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

When should levodopa be started?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

A pilot study on the motor effects of rimantadine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

The control of rubella in the Republic of Ireland

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD003468

1 reference

7 January 2021

Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003468

7 January 2021